trending Market Intelligence /marketintelligence/en/news-insights/trending/e8re44t5yauwmpzh0fap4a2 content esgSubNav
In This List

Basilea Pharmaceutica CEO to retire, board members to step down

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Basilea Pharmaceutica CEO to retire, board members to step down

Swiss drugmaker Basilea Pharmaceutica AG said Ronald Scott will retire as CEO.

David Veitch, Basilea's chief commercial officer, will replace Scott, effective April 19.

Veitch's previous roles include president of European operations at Savient Pharmaceuticals Inc. and senior vice president of Europe, the Middle East and Africa at Bristol-Myers Squibb Pharmaceuticals, a unit of Bristol-Myers Squibb Co.

Further, Daniel Lew and Thomas Rinderknecht will not stand for re-election at Basilea's annual general meeting April 18.